Thelansis

End-Stage Renal Disease (ESRD) Market Outlook Thelansis’s “End-Stage Renal Disease (ESRD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential End-Stage Renal Disease (ESRD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact o...

 End-stage renal disease (ESRD) is the irreversible stage of kidney impairment that cannot be controlled by conservative management alone and requires dialysis or kidney transplantation to maintain life. There are two levels of kidney impairment that can lead to ESRD: acute and chronic. End-stage renal disease (ESRD) implies chronic renal failure (CRF) of a degree (i.e., glomerular filtration rate, GFR<10–12 mL/min) such that life cannot be sustained long-term without dialysis. In contrast to acute kidney failure, chronic kidney failure is a permanent condition that leads to a progressive decline in renal function. Once it occurs, the kidneys cannot be made to function properly again, even when an inciting event has been corrected. CRF may exist for 10 to 20 years before progressing to ESRD. Over 70% of late-stage chronic kidney disease cases result from prolonged diabetes mellitus or hypertension. Glomerulonephritis, cystic diseases, and other urologic diseases account for anot...